GRAIL, Inc. (GRAL): Total Liabilities
$344.15M
As of 2025-12-31
$301.03M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $344.15M | -28.3% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $479.90M | +79.3% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $267.63M | n/a | 2025-03-05, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| GRAIL, Inc. (GRAL) | 2025-12-31 | $344.15M | -28.3% |
| Biodesix Inc (BDSX) | 2025-12-31 | $89.94M | +17.8% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $152.55M | +13.6% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $72.98M | +8.4% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $106.81M | +17.6% |
| Exagen Inc. (XGN) | 2025-12-31 | $40.57M | +15.4% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $107.68M | +42.8% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $110.13M | -2.2% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $96.44M | -22.3% |
Compare GRAL, BDSX, BLLN, PSNL side by side · Screen every company in Services-Medical Laboratories ↗